Results 11 to 20 of about 32,676 (224)

Anticoagulant effects of rivaroxaban, prednisone, alone and in combination, in healthy dogs

Journal of Veterinary Internal Medicine, 2022
Background The potential effects of glucocorticoid administration on rivaroxaban's anticoagulant bioactivity in dogs, and an appropriate rivaroxaban dosage regimen for dogs receiving glucocorticoid therapy are unknown. Hypothesis/Objectives The objective
Paige M. Hafner, Andrew J. Mackin, Robert W. Wills, Marjory B. Brooks, John M. Thomason   +4 more
doaj   +1 more source

Evaluation of Herb–Drug Interaction Between Danshen and Rivaroxaban in Rat and Human Liver Microsomes

Frontiers in Pharmacology, 2022
The combination of Salvia miltiorrhiza (Danshen) and rivaroxaban is a promising treatment option in clinical practice in China, but the herb–drug interaction between Danshen and rivaroxaban remains unclear.
Xu Wang, Jingjing Fa, Yuanjin Zhang, Shengbo Huang, Jie Liu, Junqing Gao, Lina Xing, Lina Xing, Zongjun Liu, Zongjun Liu, Xin Wang   +10 more
doaj   +1 more source

Real-world experience in managing atrial fibrillation in patients with renal impairment; Rivaroxaban versus warfarin

Heart Views, 2023
Background: The use of rivaroxaban in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) poses the risk of over- or underdosing. We aimed to compare rivaroxaban and warfarin in AF patients with moderate and severe renal impairment ...
Monirah Abdulrahman Albabtain, Zaid Dakheel Alanazi, Nawaf Hamoud Al-Mutairi, Ola Alyafi, Raneem Albanyan, Amr A Arafat   +5 more
doaj   +1 more source

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation [PDF]

, 2014
A John Camm,1 Pierre Amarenco,2 Sylvia Haas,3 Susanne Hess,4 Paulus Kirchhof,5,6 Martin van Eickels,4 Alexander GG Turpie71Division of Clinical Sciences, St George's, University of London, London, UK; 2Department of Neurology and Stroke Center, Paris-
Hess, S, Camm, AJ, Amarenco, Pierre, Eickels MV, Turpie, AG, Hess, Susanne, Haas, S, Turpie, Alexander G G, Kirchhof, P, van Eickels, M, Haas, Sylvia, Kirchhof, Paulus; id_orcid, Amarenco, P, Camm AJ, Hess S, Camm, John, Amarenco P, Van Eickels, Martin, Turpie AGG, Kirchhof P, Haas S   +20 more
core   +1 more source

The Study of Cost-Effectiveness of Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Who Developed Ischemic Stroke

Stroke Research and Treatment, 2021
Introduction. Rivaroxaban is a new anticoagulant providing benefits for the treatment of patients with atrial fibrillation (AF). This study is aimed at evaluating the cost-effectiveness of rivaroxaban compared to warfarin in patients with AF.
Neda Jaberi, Zahra Kavosi, Etrat Hooshmandi, Nasrin Moradi, Khosro Keshavarz, Afshin Borhani-Haghighi   +5 more
doaj   +1 more source

Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study

BMC Pharmacology and Toxicology, 2020
Background Rivaroxaban, a novel oral anticoagulant drug, is widely used in clinical practice. There is no standardized laboratory monitoring for rivaroxaban, and its plasma concentration in Chinese patients with deep vein thrombosis is unclear.
Ying Li, Liping Du, Xiaowan Tang, Yuexin Chen, Dan Mei   +4 more
doaj   +1 more source

Rivaroxaban prescribing in a Saudi tertiary care teaching hospital

Saudi Pharmaceutical Journal, 2018
Purpose: This drug utilization review (DUR) aimed to describe the use of rivaroxaban in a tertiary care teaching hospital and to audit the hospital physicians’ prescribing practice.
Ahmed Yacoob Mayet, Ahmed Ibrahim Alsaqer, Abdullah Musa Alhammad, Hussain Abdulrahman Al-Omar   +3 more
doaj   +1 more source

Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study

Analytical Cellular Pathology, 2020
Background. Pulmonary embolism (PE) is a life-threatening disease. Target-specific anticoagulant rivaroxaban is a direct factor Xa inhibitor that can be safely used without laboratory monitoring. Objective.
Yan Huang, Linli Duan, Wenjun He, Cheng Hong, Yehui Guo, Xinni Wang, Nuofu Zhang, Yanghang Chen, Tao Wang, Jian Wang, Chunli Liu   +10 more
doaj   +1 more source

Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp

Frontiers in Pharmacology, 2022
Cancer patients generally has a high risk of thrombotic diseases. However, anticoagulant therapy always aggravates bleeding risks. Rivaroxaban is one of the most widely used direct oral anticoagulants, which is used as anticoagulant treatment or ...
Tingting Zhao, Xuening Li, Yanwei Chen, Jie Du, Xiaodong Chen, Dalong Wang, Liyan Wang, Shan Zhao, Changyuan Wang, Changyuan Wang, Qiang Meng, Qiang Meng, Huijun Sun, Huijun Sun, Kexin Liu, Kexin Liu, Jingjing Wu, Jingjing Wu   +17 more
doaj   +1 more source

Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin

Gastroenterology Research and Practice, 2016
Introduction. The risk of gastrointestinal (GI) bleeding with rivaroxaban has not been studied extensively. The aim of our study was to assess this risk in comparison to warfarin. Methods.
Muhammed Sherid, Samian Sulaiman, Salih Samo, Husein Husein, Ruth Tupper, Charles Spurr, Humberto Sifuentes, Subbaramiah Sridhar   +7 more
doaj   +1 more source